XenoPort Arbaclofen Study
- Type of Study
- Neuroscience - Multiple Sclerosis
- Short Description
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
- Principal Investigator
- Angeli Mayadev, MD
- Eligibility Notes
- Male and female subjects, age 18-70, inclusive
- Has multiple sclerosis (MS) all subtypes of MS will be accepted, if disease is stable
- Subjects who have suffered an acute relapse of MS within 90 days prior to Screening, or have had more than 1 relapse within the year prior to Screening.
- Contact Name
- Caryl Tongco